Julian S. Gangolli - May 20, 2024 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)

Role
Director
Signature
/s/ Krish Krishnan, as attorney-in-fact for Julian S. Gangolli
Stock symbol
KRYS
Transactions as of
May 20, 2024
Transactions value $
-$2,827,690
Form type
4
Date filed
5/22/2024, 06:17 PM
Previous filing
May 3, 2024
Next filing
Jul 1, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRYS Common Stock Options Exercise $455K +20K $22.75 20K May 20, 2024 Direct
transaction KRYS Common Stock Sale -$1.79M -10.9K -54.65% $163.71 9.07K May 20, 2024 Direct F1
transaction KRYS Common Stock Sale -$1.17M -7.09K -78.17% $164.34 1.98K May 20, 2024 Direct F2
transaction KRYS Common Stock Sale -$328K -1.98K -100% $165.76 0 May 20, 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRYS Stock Option (Right to Buy) Options Exercise $0 -20K -100% $0.00* 0 May 20, 2024 Common Stock 20K $22.75 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction was executed in multiple trades ranging from $163.080 to $164.065. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F2 The transaction was executed in multiple trades ranging from $164.085 to $164.850. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3 The transaction was executed in multiple trades ranging from $165.160 to $166.000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4 The options were awarded on March 1, 2019 and vested monthly over a three-year period.